Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled study of ABP2111Na tablets for weight management in adults with overweight or obesity
CTR20250798Phase 2Active
- Sponsor
- EyeBio
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity and Overweight comparing ABP2111Na with Placebo (2 arms). Primary endpoints: Percent change in body weight from baseline and Proportion of participants achieving at least 5% weight loss. Started Mar 2025; status: active.
02
Drugs
ABP2111Na
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20250798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250798.